GRPH SEC-Einreichungen - Graphite Bio, Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

CIK

1815776

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Graphite Bio, Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 11, 2026	EX-99.1	LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescri Exhibit 99.1 LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights Q1 2026 total revenue of $1.9 million, including $1.7 million in VIZZ® product sales Approximately 46,000 paid prescriptions filled and over 10,000 prescribing eye care professionals from launch through Q1 2026 Together with Sarah Jessica Parker, launched the DTC campaign in Q1 2026 Expanded
May 11, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00
May 11, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 LENZ THERAPEUTICS, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission Fi
April 28, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 28, 2026	ARS	ARS Na sd aq : LE NZ 20 25 An nu al Re po rt 20 1 Lo ma s Sa nt a Fe Dr iv e, Su it e 30 0 So la na Be ac h, Ca lifo rn ia 92 07 5 le nz -t x.
April 28, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
March 24, 2026	EX-21.1	SUBSIDIARIES Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Incorporation LENZ Therapeutics Operations, Inc. Delaware LENZ Netherlands B.V. Netherlands
March 24, 2026	EX-99.1	LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of Exhibit 99.1 LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights Launched VIZZ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid prescriptions filled from launch through Q1 2026, written by mor
March 24, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-405
March 24, 2026	S-8	As filed with the Securities and Exchange Commission on March 24, 2026 As filed with the Securities and Exchange Commission on March 24, 2026 Registration No.
March 24, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2026 LENZ THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2026 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission
March 24, 2026	EX-10.13	LENZ THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY As amended December 10, 2025 Exhibit 10.13 LENZ THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY As amended December 10, 2025 LENZ Therapeutics, Inc. (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (th
March 24, 2026	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) LENZ Therapeutics, Inc. (Exact name of registrant as specified in its charter) Table 1 – Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LENZ Therapeutics, Inc.
January 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 LENZ THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2026 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission
January 7, 2026	EX-99.1	LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates Launched VIZZTM (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability Exhibit 99.1 LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates Launched VIZZTM (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025 Over 6,
December 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 LENZ THERAPEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commissi
November 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 5, 2025	EX-99.1	LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 wit Exhibit 99.1 LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights VIZZTM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 Over 2,500 ECPs prescribed VIZZ, 40% of which have prescribed multiple times, resulting in ov
November 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 LENZ THERAPEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commissio
October 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2025 LENZ THERAPEUTICS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission
September 30, 2025	EX-99.1	LENZ Therapeutics Announces Commercial Product Availability of VIZZTM in the United States VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product Exhibit 99.1 LENZ Therapeutics Announces Commercial Product Availability of VIZZTM in the United States VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyop
September 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 LENZ THERAPEUT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commiss
July 31, 2025	EX-99.1	LENZ Therapeutics Announces US FDA Approval of VIZZTM for the Treatment of Presbyopia VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adul Exhibit 99.1 LENZ Therapeutics Announces US FDA Approval of VIZZTM for the Treatment of Presbyopia VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with proven efficacy for up to 10 hours VIZZ samples and pr
July 31, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F
July 30, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001
July 30, 2025	EX-99.1	LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 88-member sales force hired and prepared to initiate sales and marketing activities immediately upon approval Executed multiple international license and commercializati
July 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 LENZ THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F
June 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 LENZ THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F
May 7, 2025	EX-99.1	LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and market Exhibit 99.1 LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Cash, cash equivalents and marketable securities of $194.1 million as of March 31, 2025 Upwardly revised anticipated cash balance at PDUFA to over $185.0 million; cash ru
May 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00
May 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 LENZ THERAPEUTICS, IN UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission Fil
April 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
April 28, 2025	ARS	ARS UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM10-K (MarkOne) ☒ ANNUALREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACTOF 1934 ForthefiscalyearendedDecember31,2024 OR o TRANSITIONREPORTPURSUANTTOSECTION13OR15(d)OFTHESECURITIESEXCHANGEACT OF1934 Forthetransitionperiodfromto Commissionfilenumber001-40532 LENZTHERAPEUTICS,INC. (Exactnameofregistrantasspecifiedinitschar
April 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 15, 2025	8-K	Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission
April 14, 2025	424B5	Up to $150,000,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-286398 PROSPECTUS SUPPLEMENT To prospectus dated April 14, 2025 Up to $150,000,000 Common Stock We have entered into a sales agreement (the “sales agreement”) with TD Securities (USA) LLC (“TD Cowen”), dated April 4, 2025, relating to shares of our common stock, par value $0.00001 per share (“common stock”), offered by this prospectus supplemen
April 14, 2025	424B3	13,070,093 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-286397 13,070,093 Shares of Common Stock This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of (i) 12,922,451 shares of common stock, par value $0.00001 per share (the “Common Stock”) held by the se
April 10, 2025	LETTER	LETTER April 10, 2025 Evert Schimmelpennink Chief Executive Officer LENZ Therapeutics, Inc.
April 10, 2025	LETTER	LETTER April 10, 2025 Evert Schimmelpennink Chief Executive Officer LENZ Therapeutics, Inc.
April 10, 2025	CORRESP	April 10, 2025 April 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: LENZ Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-286397 Acceleration Request Requested Date: April 14, 2025 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gent
April 10, 2025	CORRESP	April 10, 2025 April 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Doris Stacey Gama Re: LENZ Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-286398 Acceleration Request Requested Date: April 14, 2025 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gent
April 9, 2025	424B3	1,578,947 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-282036 PROSPECTUS 1,578,947 Shares of Common Stock This prospectus relates to the resale by the selling stockholder named in this prospectus (the “selling stockholder”) of 1,578,947 shares of common stock, par value $0.00001 per share (the “Common Stock”) that were sold and issued to the selling stockholder in a private placement pursuant to a
April 9, 2025	424B3	1,022,809 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-278393 PROSPECTUS 1,022,809 Shares of Common Stock This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of 1,022,809 shares of common stock, par value $0.00001 per share (the “Common Stock”) issued in a private
April 4, 2025	POS AM	As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No.
April 4, 2025	EX-4.3	Form of Indenture Exhibit 4.3 LENZ THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of
April 4, 2025	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F
April 4, 2025	EX-1.2	, 2025, by and between the Registrant and TD Securities (USA) LLC Exhibit 1.2 LENZ THERAPEUTICS, INC. $150,000,000 COMMON STOCK SALES AGREEMENT April 4, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: LENZ Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that
April 4, 2025	S-3	As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No.
April 4, 2025	EX-1.1	. and TD Securities (USA) LLC (incorporated by reference to Exhibit 1.1 to the Company's Form 8-K filed with the SEC on April Exhibit 1.1 LENZ THERAPEUTICS, INC. $150,000,000 COMMON STOCK SALES AGREEMENT April 4, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: LENZ Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that
April 4, 2025	POS AM	As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No.
April 4, 2025	S-3	As filed with the Securities and Exchange Commission on April 4, 2025 As filed with the Securities and Exchange Commission on April 4, 2025 Registration No.
April 4, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) LENZ Therapeutics, Inc.
April 4, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LENZ Therapeutics, Inc.
March 19, 2025	EX-4.4	Annual Report Exhibit 4.4 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the capital stock of LENZ Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) is a summary of certain provisions of the securities that are registered under Section 12 of the Securities and Exchange Act of 1934, as amended, and does not
March 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 LENZ THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2025 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission
March 19, 2025	EX-19.1	Insider Trading Policy. Exhibit 19.1 LENZ THERAPEUTICS, INC. AMENDED AND RESTATED INSIDER TRADING POLICY (Adopted on March 21, 2024; Amended and Restated on November 12, 2024) A.POLICY OVERVIEW LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securi
March 19, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LENZ Therapeutics, Inc.
March 19, 2025	EX-97.1	Compensation Recover Exhibit 97.1 LENZ THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY Adopted on March 21, 2024; Effective upon the closing of the merger contemplated by the Registration Statement on Form S-4 (File No. 333-275919) LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the
March 19, 2025	S-8	As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No.
March 19, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-405
March 19, 2025	EX-99.1	LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, Exhibit 99.1 LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025 Upon FDA approval, commercial launch activities to commence immediately with LNZ100 product availability anticipated in the fourth quarter of 2025 Cash, ca
November 14, 2024	SC 13G/A	LENZ / LENZ Therapeutics, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 lenz1015247sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Lenz Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Che
November 8, 2024	SC 13D/A	LENZ / LENZ Therapeutics, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d871919dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities)
November 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commissio
November 6, 2024	424B3	1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
November 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 6, 2024	EX-99.1	LENZ Therapeutics Reports Third Quarter 2024 Financial Results New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and Exhibit 99.1 LENZ Therapeutics Reports Third Quarter 2024 Financial Results New Drug Application (NDA) for LNZ100 for treatment of presbyopia accepted for review by the U.S. Food and Drug Administration (FDA); PDUFA target action date of August 8, 2025 CORXEL and LENZ Therapeutics announced positive topline data from Phase 3 study in China for the treatment of presbyopia Cash, cash equivalents and
November 6, 2024	424B3	1,578,947 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated September 19, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
October 28, 2024	424B3	1,578,947 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated September 19, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
October 28, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commissio
October 28, 2024	EX-99.1	CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and m Exhibit 99.1 CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more letters). The difference in efficacy was statistically signif
October 28, 2024	424B3	1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
September 19, 2024	424B3	1,578,947 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-282036 PROSPECTUS 1,578,947 Shares of Common Stock This prospectus relates to the resale by the selling stockholder named in this prospectus (the “selling stockholder”) of 1,578,947 shares of common stock, par value $0.00001 per share (the “Common Stock”) that were sold and issued to the selling stockholder in a private placement purs
September 17, 2024	CORRESP	September 17, 2024 September 17, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tim Buchmiller Re: LENZ Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-282036 Acceleration Request Requested Date: September 19, 2024 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and
September 13, 2024	LETTER	LETTER September 13, 2024 Evert Schimmelpennink President and Chief Executive Officer LENZ Therapeutics, Inc.
September 11, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) LENZ Therapeutics, Inc.
September 11, 2024	S-1	As filed with the Securities and Exchange Commission on September 11, 2024 As filed with the Securities and Exchange Commission on September 11, 2024 Registration No.
August 14, 2024	424B3	1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
August 14, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001
August 14, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission
August 14, 2024	EX-10.1	Stock Purchase Agreement by and between LENZ Therapeutics, Inc. and Ridgeback Capital Investment Exhibit 10.1 STOCK PURCHASE AGREEMENT This STOCK PURCHASE AGREEMENT (this “Agreement”) is dated as of July 14, 2024 (the “Effective Date”), by and among LENZ Therapeutics, Inc., a Delaware corporation (the “Company”), and Ridgeback Capital Investments L.P. (the “Purchaser”). WHEREAS, the Company desires to sell to the Purchaser, and the Purchaser desires to purchase from the Company, an aggregate
August 14, 2024	EX-99.1	LENZ Therapeutics Reports Second Quarter 2024 Financial Results Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase Exhibit 99.1 LENZ Therapeutics Reports Second Quarter 2024 Financial Results Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia Announced positive topline and capstone data from the Phase 3 CLARITY study Strengthened financial position with $30 million private placement from Ridgeback Capital in July 2024 Pro forma cash, c
August 12, 2024	EX-99.1	LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia Exhibit 99.1 LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia SAN DIEGO, CA – August 12, 2024 – LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first and only aceclidine-based eye drop to improve near vision in pe
August 12, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission
August 12, 2024	424B3	1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
July 29, 2024	SC 13G	LENZ / LENZ Therapeutics, Inc. / Ridgeback Capital Investments L.P. - SC 13G Passive Investment SC 13G 1 tm2420256d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No. ) UNDER THE SECURITIES EXCHANGE ACT OF 19341 LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) July 17, 2024 (Date of Event Which Requires Filing of this Statement) Check the
July 29, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 tm2420256d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that statements on Schedules 13G and/or 13D and Forms 3, 4 and 5 with respect to the securities of LENZ Therapeutics, Inc. and any amendments thereto signed by each of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of R
July 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2024 LENZ THERAPEUTICS, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F
July 15, 2024	EX-99.1	LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital Exhibit 99.1 LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital SAN DIEGO, CA – July 15, 2024 – LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that it has entered into a stock purchase
July 15, 2024	424B3	1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
May 21, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LENZ Therapeutics, Inc.
May 21, 2024	S-8	As filed with the Securities and Exchange Commission on May 21, 2024 As filed with the Securities and Exchange Commission on May 21, 2024 Registration No.
May 9, 2024	424B3	1,297,411 Shares of Common Stock PROSPECTUS SUPPLEMENT (to Prospectus dated April 10, 2024) Filed Pursuant to Rule 424(b)(3) Registration Statement No.
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission Fil
May 8, 2024	EX-99.1	LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in m Exhibit 99.1 LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission anticipated in mid-2024 Capstone data from Phase 3 CLARITY study to be presented at Key Opinion Leader event planned for June 18, 2024 Completed merger w
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00
April 11, 2024	424B3	1,297,411 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-278393 1,297,411 Shares of Common Stock This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a “selling securityholder” and, collectively, the “selling securityholders”) of 1,297,411 shares of common stock, par value $0.00001 per share (the “Common Stock”) issued in
April 9, 2024	S-1/A	As filed with the Securities and Exchange Commission on April 8, 2024 As filed with the Securities and Exchange Commission on April 8, 2024 Registration No.
April 9, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) LENZ Therapeutics, Inc.
April 8, 2024	SC 13G/A	EcoR1 Capital, LLC SC 13G/A 1 grph13ga2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Lenz Therapeutics, Inc. (f/k/a Graphite Bio, Inc.) (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) March 21, 2024 (Date of Event Which Requires Filing of this Sta
April 8, 2024	CORRESP	April 8, 2024 April 8, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Chris Edwards Re: LENZ Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-278393 Acceleration Request Requested Date: April 10, 2024 Requested Time: 4:00 p.m. Eastern Time, or as soon thereafter as practicable Ladies and Gentlemen
April 3, 2024	EX-99.1	LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials –LNZ100 selected as lead candidate –Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours – LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials –LNZ100 selected as lead candidate –Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours –Rapid onset and long duration shown with 71% of participants achieving three-lines or greater improvement at 30 minutes and 40% at 10 hours –New Drug Application submission anticipated in mid-2024 –Company to host a conference call and webcast today at 8:00 a.
April 3, 2024	EX-99.2	NASDAQ: LENZ Topline CLARITY Results Phase 3 Clinical Trials April 3rd 2024 This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not NASDAQ: LENZ Topline CLARITY Results Phase 3 Clinical Trials April 3rd 2024 This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995.
April 3, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission F
April 3, 2024	LETTER	LETTER United States securities and exchange commission logo April 3, 2024 Evert Schimmelpennink President and Chief Executive Officer LENZ Therapeutics, Inc.
March 29, 2024	EX-21.1	List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Company’s Registration Statement on Form S-1 filed with the SEC on March 29, 2024) Exhibit 21.1 SUBSIDIARIES Name Jurisdiction of Incorporation LENZ Therapeutics Operations, Inc. Delaware
March 29, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) LENZ Therapeutics, Inc.
March 29, 2024	S-1	As filed with the Securities and Exchange Commission on March 29, 2024 As filed with the Securities and Exchange Commission on March 29, 2024 Registration No.
March 28, 2024	EX-99.1	JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be
March 28, 2024	SC 13D	RA CAPITAL MANAGEMENT, L.P. - SC 13D SC 13D 1 tm2410120d1sc13d.htm SC 13D     UNITED STATES SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     SCHEDULE 13D   Under the Securities Exchange Act of 1934 (Amendment No. )*   LENZ Therapeutics, Inc. (Name of Issuer)   Common stock, $0.00001 par value per share (Title of Class of Securities)   52635N103 (CUSIP Number)   RA Capital Management, L.P. 200 Berkeley Street, 18th Floo
March 28, 2024	SC 13G	Alpha Wave Ventures GP, Ltd - LENZ THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LENZ Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) March 21, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
March 25, 2024	EX-99.11	Joint Filing Agreement EX-99.11 2 d810139dex9911.htm EX-99.11 Exhibit 11 Joint Filing Agreement The undersigned hereby agree that the attached Amendment No. 2 to Schedule 13D (or any amendment thereto) relating to the Common Stock of LENZ Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Amendment No. 2 to Schedule 13D. March 25, 2024 Vers
March 25, 2024	SC 13G	GRPH / Graphite Bio, Inc. / Point72 Asset Management, L.P. - LENZ THERAPEUTICS, INC. Passive Investment SC 13G 1 p24-1293sc13g.htm LENZ THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) March 21, 2024 (Date of Event Which Requires Filing of this Statement) Check t
March 25, 2024	SC 13D/A	GRPH / Graphite Bio, Inc. / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) Vers
March 25, 2024	SC 13G/A	GRPH / Graphite Bio, Inc. / Samsara BioCapital, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm249756d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* LENZ Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 52635N103 (CUSIP Number) March 21, 2024 (Date of Event Which Requires Filing of this Statement) Ch
March 22, 2024	8-K	Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendment to Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 LENZ THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other jurisdiction of incorporation) (Commission
March 22, 2024	EX-16.1	Letter from Deloitte & Touche LLP to the SEC, dated March 21, 2024 (incorporated by reference to Exhibit 16.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 16.1 March 21, 2024 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549-7561 Ladies and Gentlemen: We have read LENZ Therapeutics, Inc. statements (formally known as Graphite Bio, Inc.) included under Item 4.01 of its Form 8-K dated March 21, 2024 and have the following comments: 1.We are in agreement with the statements made in part (a) Dismissal of Independent Regi
March 22, 2024	EX-10.10	2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.10 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.10 LENZ THERAPEUTICS, INC. 2024 EMPLOYEE STOCK PURCHASE PLAN 1. Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee stock purchase plan” under Code
March 22, 2024	EX-3.1	Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF GRAPHITE BIO, INC. Graphite Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Graphite Bio, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Dela
March 22, 2024	EX-99.2	UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Merger On November 14, 2023, Graphite Bio, Inc., a Delaware corporation (“Graphite”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and between Graphite, Generate Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Graphite (“Merger Sub”), and Lenz Therapeutics, Inc., a Delawa
March 22, 2024	EX-10.16	Outside Director Compensation Policy (incorporated by reference to Exhibit 10.16 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.16 LENZ THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Co
March 22, 2024	EX-10.14	Employment Offer Letter between LENZ Therapeutics, Inc. and Dan Chevallard dated March 21, 2024 (incorporated by reference to Exhibit 10.14 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.14 LENZ Therapeutics, Inc. Employment Letter March 21, 2024 Dan Chevallard Via email Dear Dan: LENZ Therapeutics, Inc. (the “Company” or “we”) is pleased to offer you employment pursuant to this letter agreement (the “Agreement”), effective as of March 21, 2024 (the “Effective Date”). 1.Position. Commencing on the Effective Date, you will be employed as the Chief Financial Officer of th
March 22, 2024	EX-99.3	LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress – LENZ Therapeutics to debut on Nasdaq under the ticker symbol “LENZ” as a publicly traded company advancing late clinica Exhibit 99.3 LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress – LENZ Therapeutics to debut on Nasdaq under the ticker symbol “LENZ” as a publicly traded company advancing late clinical-stage assets for the treatment of presbyopia – – Topline data from registration-enabling Phase 3 CLARITY trials for lead assets LNZ100
March 22, 2024	EX-10.6	Form of Graphite Bio, Inc., Stockholder Support Agreement (incorporated by reference to Exhibit 10.6 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.6 GRAPHITE BIO, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November 14, 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of Parent. WHEREAS, Parent, Generate Merger
March 22, 2024	EX-10.9	2024 Equity Incentive Plan and related form agreements (incorporated by reference to Exhibit 10.9 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.9 LENZ THERAPEUTICS, INC. 2024 EQUITY INCENTIVE PLAN 1. Purposes of the Plan; Award Types. (a) Purposes of the Plan. The purposes of this Plan are to attract and retain personnel for positions with the Company Group, to provide additional incentive to Employees, Directors, and Consultants (collectively, “Service Providers”), and to promote the success of the Company’s business. (b) Awar
March 22, 2024	EX-10.12	Employment Offer Letter between LENZ Therapeutics, Inc. and Marc Odrich dated March 21, 2024 (incorporated by reference to Exhibit 10.12 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.12 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter March 21, 2024 Marc Odrich Via email Dear Marc: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is to
March 22, 2024	EX-10.21	Registration Rights Agreement, dated March 21, 2024, by and among LENZ Therapeutics, Inc. and certain parties thereto (incorporated by reference to Exhibit 10.21 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.21 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is made as of March 21, 2024, by and among Graphite Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), and the several investors signatory hereto (each, an “Investor” and collectively, the “Investors”). RECITALS WHEREAS, the Company is party to that
March 22, 2024	EX-10.11	Employment Offer Letter between LENZ Therapeutics, Inc. and Evert Schimmelpennink dated March 21, 2024 (incorporated by reference to Exhibit 10.11 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.11 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter March 21, 2024 Evert Schimmelpennink Via email Dear Evert: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agre
March 22, 2024	EX-10.8	Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.8 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.8 LOCK-UP AGREEMENT November 14, 2023 Graphite Bio, Inc. 611 Gateway Blvd., Suite 120 San Francisco, CA 94080 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Graphite Bio, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of November 14, 2023 (as the same may be amende
March 22, 2024	EX-10.7	Form of LENZ Therapeutics, Inc., Stockholder Support Agreement (incorporated by reference to Exhibit 10.7 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.7 LENZ THERAPEUTICS, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November 14, 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREAS, Parent, Gener
March 22, 2024	EX-99.1	Report of Independent Registered Public Accounting Firm Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Lenz Therapeutics, Inc.
March 22, 2024	EX-10.13	Employment Offer Letter between LENZ Therapeutics, Inc. and Shawn Olsson dated March 21, 2024 (incorporated by reference to Exhibit 10.13 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024). Exhibit 10.13 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter March 21, 2024 Shawn Olsson Via email Dear Shawn: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is
March 19, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Graphite Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40532 83-4867570 (State or other jurisdiction of incorporation) (Commission File
March 14, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Graphite Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40532 83-4867570 (State or other jurisdiction of incorporation) (Commission File
March 8, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Graphite Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other Jurisdiction of Incorporation) (Commission File N
March 8, 2024	EX-99.1	Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger Exhibit 99.1 Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics Special dividend estimated to be $1.03 per share Payment of special dividend conditioned upon closing of merger SOUTH SAN FRANCISCO, CA – March 8, 2024 – Graphite Bio, Inc. (Nasdaq: GRPH) (“Graphite” or the “Company”) today announced that its Board of Directors has declared a special divid
March 8, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Graphite Bio, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 Graphite Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40532 84-4867570 (State or other Jurisdiction of Incorporation) (Commission File N
March 5, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N
March 5, 2024	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Graphite Bio, Inc. 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi
February 27, 2024	EX-21.1	Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF GRAPHITE BIO, INC. None.
February 27, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC.
February 27, 2024	EX-10.27	Compensation Recovery Policy Exhibit 10.27 GRAPHITE BIO, INC. COMPENSATION RECOVERY POLICY Adopted as of November 14, 2023 Graphite Bio, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defi
February 13, 2024	REDACTED EXHIBIT	REDACTED EXHIBIT February 13, 2024 Kimberlee C. Drapkin Chief Executive Officer Graphite Bio, Inc. 611 Gateway Blvd., Suite 120 San Francisco, CA 94080 Re: Graphite Bio, Inc. Amendment No. 3 to Registration Statement on Form S-4 Exhibit Nos. 10.30, 10.45, and 10.46 Filed February 9, 2024 File No. 333-275919 Dear Kimberlee C. Drapkin: We have concluded our assessment of your redacted exhibits for compliance with ap
February 13, 2024	424B3	PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-275919 PROPOSED MERGER YOUR VOTE IS VERY IMPORTANT To the Stockholders of Graphite Bio, Inc. and Lenz Therapeutics, Inc., Graphite Bio, Inc., a Delaware corporation (“Graphite”), and Lenz Therapeutics, Inc., a Delaware corporation (“LENZ”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) on November 14, 2
February 9, 2024	CORRESP	Graphite Bio, Inc. 611 Gateway Blvd, Suite 120 South San Francisco, CA 94080 Graphite Bio, Inc. 611 Gateway Blvd, Suite 120 South San Francisco, CA 94080 February 9, 2024 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street NE Washington, DC 20549 Attention: Ms. Doris Stacey Gama Mr. Jason Drory Mr. Eric Atallah Ms. Lynn Dicker Re: Graphite Bio, Inc. Acceleration Request for Registration Statement on F
February 9, 2024	S-4/A	As filed with the Securities and Exchange Commission on February 9 , 2024 No. 333-275919 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graph Table of Contents As filed with the Securities and Exchange Commission on February 9 , 2024 No.
February 9, 2024	LETTER	LETTER United States securities and exchange commission logo February 9, 2024 Kimberlee Drapkin Chief Executive Officer Graphite Bio, Inc.
February 9, 2024	CORRESP	***** Goodwin Procter The New York Times Building 620 Eighth Avenue New York, NY 10018 VIA EDGAR February 9, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
February 5, 2024	EX-10.45	Asset Purchase Agreement, by and between Maro Bio Inc. and Graphite Bio, Inc., dated August 1, 2023. Exhibit 10.45 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. Execution Version ASSET PURCHASE AGREEMENT by and between MARO BIO INC., a Delaware corporation and GRAPHITE BIO, INC., a Dela
February 5, 2024	S-4/A	As filed with the Securities and Exchange Commission on February 5, 2024 No. 333-275919 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graphi Table of Contents As filed with the Securities and Exchange Commission on February 5, 2024 No.
February 5, 2024	SC 13G	GRPH / Graphite Bio, Inc. / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 5, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.00001 par value per share, of Graphite Bio, Inc. and further agree to the filing of thi
February 5, 2024	EX-10.46	License and Option Agreement, by and between Kamau Therapeutics, Inc. and Graphite Bio, Inc., dated August 4, 2023, as amended on September 12, 2023. EXHIBIT 10.46 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. LICENSE AND OPTION AGREEMENT This License and Option Agreement (this “Agreement”) is entered into as of August 4, 2023 (the “E
February 5, 2024	SC 13G/A	GRPH / Graphite Bio, Inc. / Porteus Matthew - SC 13G/A Passive Investment SC 13G/A 1 d710000dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* GRAPHITE BIO, INC. (Name of Issuer) Common Stock, Par Value $0.00001 Per Share (Title of Class of Securities) 38870X104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check
February 5, 2024	CORRESP	***** Goodwin Procter The New York Times Building 620 Eighth Avenue New York, NY 10018 VIA EDGAR February 5, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
February 1, 2024	REDACTED EXHIBIT	REDACTED EXHIBIT February 1, 2024 Kimberlee C. Drapkin Chief Executive Officer Graphite Bio Inc. 611 Gateway Blvd., Suite 120 San Francisco, CA 94080 Re: Graphite Bio Inc. Amendment No. 1 to Registration Statement on Form S-4 Exhibit No. 10.30 Filed January 18, 2024 File No. 333-275919 Dear Kimberlee C. Drapkin: You have redacted information from the exhibit identified above asserting that the redacted information
February 1, 2024	LETTER	LETTER United States securities and exchange commission logo January 31, 2024 Kimberlee Drapkin Chief Executive Officer Graphite Bio, Inc.
January 18, 2024	EX-21.1	List of Subsidiaries of Graphite Bio, Inc. Exhibit 21.1 SUBSIDIARIES OF GRAPHITE BIO, INC. Legal Name State of Organization Generate Merger Sub, Inc. Delaware
January 18, 2024	EX-99.2	Consent of Jeff George to serve as a director of Graphite Bio, Inc., to be renamed LENZ Therapeutics, Inc. Exhibit 99.2 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme
January 18, 2024	EX-10.44	Form of Indemnification Agreement (incorporated by reference to Exhibit 10.44 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 9, 2024). Exhibit 10.44 LENZ THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this “Agreement”) is dated as of [insert date], and is between LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.), a Delaware corporation (the “Company”), and [insert name of indemnitee] (“Indemnitee”). RECITALS A. Indemnitee’s service to the Company substantially benefits the Company. B. Ind
January 18, 2024	EX-10.30	License and Collaboration Agreement by and between LENZ and Ji Xing Pharmaceuticals Hong Kong Limited, dated April 12, 2022 (incorporated by reference to Exhibit 10.30 to the Company’s Registration Statement on Form S-4 filed with the SEC on January 18, 2024). Exhibit 10.30 [***] Certain information in this document has been omitted from this exhibit pursuant to Item 601(b) of Regulation S-K because it is both not material and is the type that the Registrant treats as private or confidential. LICENSE AND COLLABORATION AGREEMENT This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of April 12th, 2022 (the “Effective Date”) by an
January 18, 2024	S-4/A	As filed with the Securities and Exchange Commission o n Jan uary 17 , 2024 No. 333-275919 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Gra Table of Contents As filed with the Securities and Exchange Commission o n Jan uary 17 , 2024 No.
January 17, 2024	CORRESP	***** Goodwin Procter The New York Times Building 620 Eighth Avenue New York, NY 10018 VIA EDGAR January 17, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
January 5, 2024	LETTER	LETTER United States securities and exchange commission logo January 4, 2024 Kimberlee Drapkin Chief Executive Officer Graphite Bio, Inc.
December 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Graphite Bio, I UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi
December 26, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Graphite Bio, I 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commissio
December 6, 2023	EX-99.8	Consent of Leerink Partners LLC. Exhibit 99.8 CONSENT OF LEERINK PARTNERS LLC We hereby consent to the use of our opinion letter dated November 14, 2023, to the Board of Directors of Graphite Bio, Inc., included as Annex B to the proxy statement/prospectus which forms a part of the Registration Statement on Form S-4 of Graphite Bio, Inc., to be filed on the date hereof, and to the references to such opinion in such proxy statemen
December 6, 2023	EX-4.4	Amended and Restated By-Laws of LENZ Therapeutics, Inc., as currently in effect. Exhibit 4.4 Amended and Restated BY-LAWS OF Lenz Therapeutics, Inc. (a Delaware corporation) Adopted by the Sole Incorporator on October 28, 2020 Affirmed by the Board of Directors on October 30, 2020 Amended and restated on March 1, 2023 Amended and Restated BY-LAWS OF Lenz Therapeutics, Inc. ARTICLE 1.- Stockholders 1.1 Place of Meetings. All meetings of stockholders shall be held at such place
December 6, 2023	EX-4.5	Form of Warrant to Purchase Shares of Series A Preferred Stock (incorporated by reference to Exhibit 4.5 to the Company’s Registration Statement on Form S-4 filed with the SEC on December 6, 2023). Exhibit 4.5 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGI
December 6, 2023	EX-FILING FEES	Filing fee table. Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) GRAPHITE BIO, INC.
December 6, 2023	EX-99.6	Consent of Zach Scheiner to serve as a director of Graphite Bio, Inc., to be renamed LENZ Therapeutics, Inc. Exhibit 99.6 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme
December 6, 2023	EX-10.31	2020 Equity Incentive Plan and related form agreements (incorporated by reference to Exhibit 10.31 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 9, 2024). Exhibit 10.31 PRESBYOPIA THERAPIES, INC. 2020 EQUITY INCENTIVE PLAN Adopted by the Board of Directors on October 30, 2020 Approved by the Stockholders on November 3, 2020 1. Purposes of the Plan. The purposes of this 2020 Equity Incentive Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Employees and Consult
December 6, 2023	EX-10.42	Outside Director Compensation Policy, to be in effect upon completion of the merger. Exhibit 10.42 LENZ THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (the “Company”) believes that providing cash and equity compensation to members of its Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Co
December 6, 2023	EX-10.40	Form of Employment Offer Letter between LENZ Therapeutics, Inc., and Marc Odrich, to be in effect upon completion of the merger. Exhibit 10.40 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter , 2024 Marc Odrich Via email Dear Marc: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is to confirm
December 6, 2023	EX-10.39	Form of Employment Offer Letter between LENZ Therapeutics, Inc., and Shawn Olsson, to be in effect upon completion of the merger. Exhibit 10.39 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter , 2024 Shawn Olsson Via email Dear Shawn: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is to confi
December 6, 2023	EX-10.43	Employee Incentive Compensation Plan (incorporated by reference to Exhibit 10.43 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 9, 2024). Exhibit 10.43 LENZ THERAPEUTICS, INC. EMPLOYEE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. 2.1 “Actual Award” means as to any Performance Period, the actual award (if any) payable t
December 6, 2023	EX-99.5	Consent of James McCollum to serve as a director of Graphite Bio, Inc., to be renamed LENZ Therapeutics, Inc. Exhibit 99.5 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme
December 6, 2023	EX-99.3	Consent of Evert Schimmelpennink to serve as a director of Graphite Bio, Inc., to be renamed LENZ Therapeutics, Inc. Exhibit 99.3 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme
December 6, 2023	EX-21.2	List of Subsidiaries of Graphite Bio, Inc. Exhibit 21.2 SUBSIDIARIES OF GRAPHITE BIO, INC. None.
December 6, 2023	EX-99.4	Consent of Frederic Guerard to serve as a director of Graphite Bio, Inc., to be renamed LENZ Therapeutics, Inc. Exhibit 99.4 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme
December 6, 2023	EX-4.6	Warrant to Purchase Shares of LENZ Common Stock, dated December 19, 2020. Exhibit 4.6 THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (THIS “WARRANT”) AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THIS WARRANT AND SUCH SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE OFFERED, SOLD,
December 6, 2023	EX-4.3	Amended and Restated Certificate of Incorporation of LENZ Therapeutics, Inc., as currently in effect. Exhibit 4.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF LENZ THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) LENZ THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. That th
December 6, 2023	EX-10.29	Standard Multi-Tenant Office Lease – Gross by and between LENZ and Hankey Investment Company, L.P. dated February 4, 2022, as amended March 21, 2023 (incorporated by reference to Exhibit 10.29 to the Company’s Registration Statement on Form S-4 filed with the SEC on February 9, 2024). Exhibit 10.29 AIR STANDARD MULTI-TENANT OFFICE LEASE - GROSS 1. Basic Provisions (“Basic Provisions”). 1.1 Parties. This Lease (“Lease”), dated for reference purposes only February 4, 2022 ,1s made by and between Hankey Investment Company, L.P., a California limited partnership (“Lessor”)and Lenz Therapeutics, Inc., a Delaware corporation (“Lessee”), (collectively the “Parties”, or Individually a
December 6, 2023	S-4	As filed with the Securities and Exchange Commission on December 6, 2023 No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Graphite Bio, Inc. (Exact name Table of Contents As filed with the Securities and Exchange Commission on December 6, 2023 No.
December 6, 2023	EX-99.7	Consent of Shelley Thunen to serve as a director of Graphite Bio, Inc., to be renamed LENZ Therapeutics, Inc. Exhibit 99.7 Consent to be Named as a Director In connection with the filing by Graphite Bio, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendme
December 6, 2023	EX-10.41	Executive Change in Control and Severance Policy and form of participation agreement (incorporated by reference to Exhibit 10.41 to the Company’s Registration Statement on Form S-4 filed with the SEC on December 6, 2023). Exhibit 10.41 LENZ THERAPEUTICS, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE POLICY This Executive Change in Control and Severance Policy (the “Policy”) is designed to provide certain protections to a select group of key employees of LENZ Therapeutics, Inc. (previously named Graphite Bio, Inc.) (“Lenz” or the “Company”) or any of its subsidiaries if their employment is involuntarily terminated
December 6, 2023	EX-10.38	Form of Employment Offer Letter between LENZ Therapeutics, Inc., and Evert Schimmelpennink, to be in effect upon completion of the merger. Exhibit 10.38 LENZ THERAPEUTICS, INC. Confirmatory Employment Letter , 2024 Evert Schimmelpennink Via email Dear Evert: This letter agreement (the “Agreement”) is entered into between LENZ Therapeutics, Inc. (the “Company” or “we”) and you. This Agreement is effective as of the later of the Closing (as defined below) or the date signed below (the “Effective Date”). The purpose of this Agreement is
November 17, 2023	SC 13D/A	GRPH / Graphite Bio Inc / Versant Venture Capital VI, L.P. - SC 13D/A Activist Investment SC 13D/A 1 d598930dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 3887
November 15, 2023	425	Graphite Bio and LENZ Therapeutics Graphite Bio and LENZ Therapeutics Merger Agreement Conference Call November 15, 2023 Filed by Graphite Bio, Inc. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Graphite Bio, Inc. Commission File No.: 001-40532 Date: November 15, 2023 This filing relates to the proposed transaction pursuant to the terms of that certain Agreement and Plan of Merger, dated as of November 14, 202
November 15, 2023	EX-10.4	Subscription Agreement, dated November 14, 2023, by and among Graphite Bio, Inc. and certain parties thereto (incorporated by reference to Exhibit 10.4 to the Company’s Form 8-K filed with the SEC on November 15, 2023). Exhibit 10.4 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Agreement”) is dated as of November 14, 2023 (the “Effective Date”), by and among Graphite Bio, Inc., a Delaware corporation (the “Company”), and the individuals and entities listed on Exhibit A attached to this Agreement (each, a “Purchaser” and together, the “Purchasers”). WHEREAS, the Company is party to that certain Agreeme
November 15, 2023	EX-10.1	Form of Graphite Bio, Inc. Stockholder Support Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40532) filed on November 15, 2023). Exhibit 10.1 GRAPHITE BIO, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November [•], 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of Parent. WHEREAS, Parent, Generate Merge
November 15, 2023	425	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Graphite Bio, I 425 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commissio
November 15, 2023	EX-10.3	Form of Lock-Up Agreement Exhibit 10.3 LOCK-UP AGREEMENT , 2023 Graphite Bio, Inc. 611 Gateway Blvd., Suite 120 San Francisco, CA 94080 Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement”) understands that Graphite Bio, Inc., a Delaware corporation (“Parent”), has entered into an Agreement and Plan of Merger, dated as of November [•], 2023 (as the same may be amended from tim
November 15, 2023	EX-10.2	Form of LENZ Support Agreement Exhibit 10.2 LENZ THERAPEUTICS, INC. SUPPORT AGREEMENT THIS SUPPORT AGREEMENT (this “Agreement”), dated as of November [•], 2023 is made by and among Graphite Bio, Inc., a Delaware corporation (“Parent”), Lenz Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holders (each a “Stockholder”) of shares of capital stock (the “Shares”) of the Company. WHEREAS, Parent, Gene
November 15, 2023	8-K	Regulation FD Disclosure, Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 15, 2023	EX-99.2	Legends Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied s Exhibit 99.2 + Merger Announcement November 2023 Legends Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, express or implied statements regarding the structure, timing and completion of the proposed merger by and between Graphi
November 15, 2023	EX-2.1	Agreement and Plan of Merger, dated as of November 14, 2023, by and among Graphite Bio, Inc., Generate Merger Sub, Inc. and LENZ Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 15, 2023). Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among GRAPHITE BIO, INC., GENERATE MERGER SUB, INC. and LENZ THERAPEUTICS, INC. Dated as of November 14, 2023 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 3 Section 1.1 Certain Definitions 3 Section 1.2 Interpretation 9 Section 1.3 Currency 9 ARTICLE II THE MERGER 10 Section 2.1 Formation of Merger Sub 10 Section 2.2 The Merger 10 S
November 15, 2023	EX-99.1	LENZ Therapeutics and Graphite Bio Announce Merger Agreement - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia - Combined company expect Exhibit 99.1 LENZ Therapeutics and Graphite Bio Announce Merger Agreement - Merger to create NASDAQ-listed, late clinical-stage biopharmaceutical company focused on advancing LENZ Therapeutics’ lead assets for the treatment of presbyopia - Combined company expected to have approximately $225 million of cash or cash equivalents at close, including $53.5 million from a concurrent PIPE financing - Co
November 13, 2023	EX-10.2	Separation and Release Agreement, by and between Graphite Bio, Inc. and Josh Lehrer, dated September 7, 2023 (incorporated by reference to Exhibit 10.2 to Graphite Bio, Inc.’s Quarterly Report on Form 10-Q (File No. 001-40532) filed on November 13, 2023). Exhibit 10.2 GRAPHITE BIO, INC. September 5, 2023 PERSONAL AND CONFIDENTIAL Josh Lehrer Re: Separation Agreement and Release Dear Josh: This letter confirms our previous discussions concerning your employment with Graphite Bio, Inc. (the “Company”). On August 21, 2023 (the “Termination Date”), your employment with the Company shall end and your status with the Company shall change to no longer emp
November 13, 2023	EX-10.1	Employment Offer Letter, by and between Graphite Bio, Inc. and Kimberlee C. Drapkin, dated August 21, 2023 (incorporated by reference to Exhibit 10.1 to Graphite Bio, Inc.’s Quarterly Report on Form 10-Q (File No. 001-40532) filed on November 13, 2023). Exhibit 10.1 August 18, 2023 Kim Drapkin Via Electronic Delivery Dear Kim: It is my great pleasure to present this offer letter to you to join Graphite Bio, Inc. (the “Company”) as our Chief Executive Officer. The entire board of directors of the Company (the “Board”) and I are very excited to have you as a member of the Graphite Bio team. Your experiences and accomplishments are consistent with t
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC.
October 30, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fil
October 30, 2023	EX-10.1	Sublease agreement by and between Graphite Bio, Inc. and Soleil Labs, LLC, dated October 26, 2023 Exhibit 10.1 SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of October 26, 2023, and is made by and between Graphite Bio, Inc., a Delaware corporation (“Sublessor”), and Soleil Labs, LLC, a Delaware limited liability company (“Sublessee”). Sublessor and Sublessee hereby agree as follows: 1. Recitals: This Sublease is made with reference to the fact that BAYSIDE AREA DE
October 30, 2023	EX-10.2	First Amendment to Lease by and between Graphite Bio, Inc. and Bayside Area Development, LLC, dated October 26, 2023 Exhibit 10.2 FIRST AMENDMENT TO LEASE This First Amendment to Lease (this "Amendment") is entered into as of the 26th day of October, 2023 (the “Amendment Effective Date”), by and between BAYSIDE AREA DEVELOPMENT, LLC, a Delaware limited liability company (" XE "Landlord" Landlord"), and GRAPHITE BIO, INC., a Delaware corporation (" XE "Tenant" Tenant"). r e c i t a l s : A. Landlord and Tenant en
September 13, 2023	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporati
August 23, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Costs Associated with Exit or Disposal Activities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File
August 14, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC.
August 2, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N
June 23, 2023	EX-99.1	Graphite Bio Announces Departure of Chief Financial Officer Exhibit 99.1 Graphite Bio Announces Departure of Chief Financial Officer SOUTH SAN FRANCISCO, Calif., June 23, 2023 – Graphite Bio, Inc. (Nasdaq: GRPH) today announced that Alethia Young, the Company’s Chief Financial Officer, will step down from her position to pursue other opportunities. Ms. Young will remain with the Company through June 30, 2023 to oversee her current responsibilities and ensu
June 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File N
June 6, 2023	ARS	ARS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC.
June 6, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
June 6, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC.
April 27, 2023	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K/A Amendment No.
March 20, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 grph-exfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Graphite Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amoun
March 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File
March 20, 2023	EX-99	Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results Exhibit 99.1 Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results SOUTH SAN FRANCISCO, Calif., March 20, 2023 – Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results. “As announced last month, Graphite Bio has initiated a process to evaluate strategic alternatives that m
March 20, 2023	EX-21	Subsidiaries of the Registrant. Exhibit 21.1 SUBSIDIARIES OF GRAPHITE BIO, INC. None.
March 20, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC.
March 20, 2023	EX-10	Master Development and Manufacturing Services Agreement (for cell therapy services), by and between WuXi Advanced Therapies Inc. and Registrant, dated November 7, 2022. Exhibit 10.24 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. MASTER DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (for cell therapy services) This Master Developm
March 20, 2023	S-8	As filed with the Securities and Exchange Commission on March 20, 2023 As filed with the Securities and Exchange Commission on March 20, 2023 Registration No.
March 16, 2023	EX-10	Form of Retention and Severance Agreement (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-40532) filed on March 16, 2023). , 2023 [NAME] [ADDRESS] RE: Retention and Severance Agreement Dear [NAME]: The Compensation Committee (“Committee”) of the Board of Directors (the “Board”) of Graphite Bio, Inc.
March 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File
February 22, 2023	EX-99	Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring EX-99 2 grph-ex991.htm EX-99.1 Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring SOUTH SAN FRANCISCO, Calif., February 22, 2023 – Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of n
February 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi
February 14, 2023	SC 13G/A	GRPH / Graphite Bio, Inc. / Samsara BioCapital, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236534d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 38870X104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Chec
January 9, 2023	SC 13G/A	GRPH / Graphite Bio, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 grph13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 38870X104 (CUSIP Number) January 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t
January 5, 2023	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 05, 2023 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fil
January 5, 2023	EX-99.1	Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease Exhibit 99.1 Exhibit 99.1 Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease SOUTH SAN FRANCISCO, Calif., January 5, 2023 ? Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious advers
December 12, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi
December 12, 2022	SC 13G/A	GRPH / Graphite Bio, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No.2 GRAPHITE BIO INC COMMON STOCK Cusip #38870X104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #38870X104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 1,672,756 Item 6: 0 Item 7: 1,673,344 Item 8: 0 Item 9: 1,673,344 Item 11: 2.877
December 12, 2022	EX-99.1	Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients Exhibit 99.1 Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) SOUTH SAN FRANCISCO, Calif., December 11, 2022 – Graphite Bio, Inc. (Nasdaq: GRPH),
November 18, 2022	SC 13G	GRPH / Graphite Bio, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Graphite Bio, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 38870X104 (CUSIP Number) November 11, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q w UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC.
November 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 9, 2022	EX-99.1	Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Expositio Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results Dosed first sickle cell patient with nula-cel; initial proof-of-concept data on track for mid-2023 Two abstracts accepted for 64th ASH Annual Meeting and Exposition in December Entered strategic partnership with Philadelphia-based WuXi Advanced Therapies for the manufacturing of nula-cel Bolstered company leadership with hiring of senior vice president of development $305.
November 3, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission Fi
November 3, 2022	EX-99.1	Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition Exhibit 99.1 Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition SOUTH SAN FRANCISCO, Calif., November 3, 2022 ? Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced th
August 11, 2022	EX-99.1	Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results Dosed first patient with nulabeglogene autogedtemcel (nula-cel), formerly known as GPH101, in Phase 1/2 CEDAR clinical trial in people with sickle cell disease; i Exhibit 99.1 Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results Dosed first patient with nulabeglogene autogedtemcel (nula-cel), formerly known as GPH101, in Phase 1/2 CEDAR clinical trial in people with sickle cell disease; initial proof-of-concept data now anticipated in mid-2023 Presented preclinical gene replacement data for GPH102 in beta-thalassemia at AS
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40532 GRAPHITE BIO, INC.
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File
August 11, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022 Graphite Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40532 84-4867570 (State or Other Jurisdiction of Incorporation) (Commission File
August 11, 2022	EX-99.1	Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease GPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that causes sickle cell disease Ini Exhibit 99.1 Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease GPH101, now called nulabeglogene autogedtemcel (nula-cel), designed to directly correct the genetic mutation that causes sickle cell disease Initial proof-of-concept data from Phase 1/2 CEDAR trial anticipated in mid-2023 SOUTH SAN FRANCISCO, Calif., August 11, 2022 ? Graphite Bio
July 26, 2022	CORRESP	Graphite Bio, Inc. 201 Haskins Way, Suite 210 South San Francisco, CA 94080 Graphite Bio, Inc. 201 Haskins Way, Suite 210 South San Francisco, CA 94080 July 26, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Graphite Bio, Inc.: Registration Statement on Form S-3 filed July 21, 2022 (File No. 333-266262) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities
July 26, 2022	LETTER	LETTER United States securities and exchange commission logo July 26, 2022 Josh Lehrer Chief Executive Officer Graphite Bio, Inc.
July 21, 2022	EX-4.4	Form of indenture for senior debt securities and the related form of senior debt security. Exhibit 4.4 GRAPHITE BIO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page Article 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 Article 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities. 4 Section 2.02 Form of Securities and Trustee?s Certificate 6 Sect
July 21, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 CALCULATION OF REGISTRATION FEE Form S-3 (Form Type) Graphite Bio, Inc. (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration
July 21, 2022	EX-1.2	Controlled Equity OfferingSM Sales Agreement, dated July 21, 2022, by and between the Registrant and Cantor Fitzgerald & Co. Exhibit 1.2 GRAPHITE BIO, INC. Shares of Common Stock (par value $0.00001 per share) Controlled Equity OfferingSM Sales Agreement July 21, 2022 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Graphite Bio, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), as follows: 1. Issuance and S

GRPH / Graphite Bio, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?